tapebrief
GL · Q2 2025

GL · Q3 2025 Earnings

Bullish

Globe Life

Reported October 22, 2025

30-second summary

Globe Life printed $4.81 non-GAAP EPS on $1.51B revenue (+3.9% YoY). Reported life underwriting margin was ~57% of premium, but that includes a $130.9M life assumption-update remeasurement gain plus ~$18M of additional favorable life experience; normalized life UW margin was 41.5% (vs. 40.4% prior-year quarter), slightly below the prior 43–45% Q3 guide band. Health printed ~28% reported / 27.2% normalized — in-band. Management narrowed FY2025 EPS to $14.40–$14.60 (midpoint +$0.05, high end clipped $0.05), raised the FY2025 life UW margin band to 44–46%, lifted FY2025 buybacks to ~$685M (from $600–650M), and initiated FY2026 EPS at $14.60–$15.30 (+3% at midpoint per management). DTC life premium remains -0.6% YoY, agent recruiting is accelerating (AIL hires +17%), and the Bermuda captive remains the unresolved binary set up last quarter.

Headline numbers

EPS

Q3 FY2025

$4.81

Revenue

Q3 FY2025

$1.51B

+3.9% YoY

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$1.51B+3.9%$1.48B+2.2%
EPS$4.81—$3.27+47.1%

Guidance

Globe Life narrowed FY2025 EPS guidance midpoint slightly to $14.50 while raising FY2026 outlook to $14.60–$15.30; Q3 underwriting margins beat substantially on better-than-expected mortality and health performance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Life Underwriting Margin (% of Premium)Q3 FY202543% to 45%~56.9%+11.9 to +13.9 pts above high end of guideMet
Health Underwriting Margin (% of Premium)Q3 FY202525% to 27%~28.0%+1.0 to +3.0 pts above high end of guideBeat
Remeasurement Gains (Q3)Q3 FY2025$110 million to $160 million——Met

New guidance

MetricPeriodGuideYoY
Net Operating Income Per ShareFY2026$14.60 to $15.30—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Net Operating Income Per Share
FY2025
$14.25 to $14.65$14.40 to $14.60Low end raised by $0.15, high end lowered by $0.05; midpoint narrowed from $14.45 to $14.50Lowered

Reaffirmed unchanged this quarter: Life Premium Revenue Growth (around 3.5%), Health Premium Revenue Growth (8% to 9%)

Segment performance

Q3 FY2025
SegmentQ3 FY2025YoY
Life Insurance Premium$0.844B+3.1%
Health Insurance Premium$0.387B+9.2%
American Income Life Division - Life Premium$0.451B+5.5%
Direct to Consumer Division - Life Premium$0.245B-0.6%
Liberty National Division - Life Premium$0.098B+4.9%
Family Heritage Division - Health Premium$0.119B+10.0%
United American Division - Health Premium$0.17B+13.8%

Capital & returns

Q3 FY2025
SegmentQ3 FY2025
Net Operating Income ROE (9M 2025)16.6%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Life Underwriting Margin$481.6 million
Health Underwriting Margin$108.4 million
Insurance Underwriting Income$503.1 million
Excess Investment Income$36.9 million ($0.45 per share)
Life Net Sales Growth2%
Health Net Sales Growth21%
Producing Agent Count - Family Heritage1,553 agents (9% YoY growth)

Management tone

Q1 capital-flexibility narrative → Q2 mortality-tailwind reaffirmation → Q3 multi-year confidence signal.

The structural shift this quarter is the FY2026 EPS initiation at $14.60–$15.30. Globe Life has historically issued FY guidance one year at a time; putting a 2026 number on the table in October 2025 is a confidence statement, not a routine update. Management framed FY2026 growth as +3% at the midpoint and explicitly called out that the lower-than-historical growth rate reflects the high bar set by the 2025 assumption updates.

Underwriting-margin commentary has migrated from "favorable mortality" hedged language in Q2 to a normalized run-rate disclosure. Q3 2025 normalized life UW margin was 41.5%, up from 40.4% in the year-ago quarter — a measured improvement that management is willing to anchor multi-year guidance to. The FY2026 life UW margin guide is 40–43% (vs. the raised FY2025 band of 44–46%), explicitly stepping down because the 2025 assumption-update gain does not recur.

Agent-recruitment framing sharpened from a generic 2026 leading indicator (Q2) to specific operational levers. Management quantified AIL hires +17% YoY, cited the new worksite enrollment platform producing 20%+ premium-per-worksite gains in early rollouts, and flagged an enterprise-wide rollout into early 2026 alongside a recruiting CRM at Liberty National. The 2026 sales-reacceleration thesis now has named tooling behind it.

The capital-return story also stepped up: management raised the FY2025 buyback target to ~$685M (from $600–650M), funded in part by a newly-approved extraordinary dividend from a subsidiary, and guided FY2026 parent excess cash flow of $600–700M (above 2025 ex-extraordinary dividends).

The notable softening: the Q4 EPS implied by the tightened FY range is conservative because Q3 benefited from items management explicitly told analysts will not repeat (R&D tax credit timing, ~$18M of favorable life experience on top of the assumption update, favorable Q3 health experience, and a typical Q4 seasonal claims uptick). That candor is itself a tone signal — management is willing to surface non-recurring drivers rather than let analysts back into them.

Q&A highlights

Jack Matten · BMO Capital Markets

What's driving muted life sales growth in exclusive agencies—consumer demand weakness or agent productivity issues? What gives confidence that life sales will reaccelerate?

No consumer demand weakness observed; premium per sale improving. Growth follows high-growth years as new agents onboard and move to middle management. Recruiting pipeline indicators (AIL hires up 17%) and incentive programs focused on agent count growth provide confidence for 2026 reacceleration.

AIL hires up 17% this quarterPremium per sale improvingRecruiting pipeline strengthening2026 expected to have higher agent count growth

Andrew Kligerman · TD Cowen

Can you elaborate on the new worksite enrollment platform and recruiting CRM at Liberty National? How do they work and why will they drive impact?

Worksite platform brings needs-based analysis tools to agents, showing 20%+ premium production increases in early rollouts; will be enterprise-wide by early 2026. Recruiting CRM consolidates manual tracking into real-time system with data analytics for agency owners and middle managers to manage conversion points in recruiting pipeline.

Worksite platform showing 20%+ increases in premium production per worksiteEnterprise-wide rollout expected early 2026Recruiting CRM tracks recruitment lifecycle in real-timeLiberty National 75% of business marketed at worksites

Jimmy Buehler · J.P. Morgan

Q4 2025 implied EPS guidance appears conservative relative to Q3 results. What explains this? Also, what are expectations for health claims trends and Medicare Advantage competitive dynamics?

Q3 benefited from favorable items (R&D tax credit timing, favorable mortality remeasurement $18M) not expected to repeat in Q4. Seasonal claims uptick anticipated in Q4. Health margins recovering as 2025 rate increases fully effective; 2026 rate increases (implemented throughout year) will further improve profitability. Medicare Advantage disruption providing tailwind for Medicare Supplement sales.

Q3 life remeasurement gain (excluding assumption changes) $18 millionQ3 and Q4 mortality experience fluctuates; Q4 typical seasonal claims increase expected2026 health rate increases becoming effective throughout yearMedical claim cost trends flattening

Tom Gallagher · Evercore ISI

How much earnings boost from Q3 long-term assumption changes? Are there assumption change benefits embedded in 2026 guidance?

Normalized life underwriting margins improved from 40% (2024) to 41% (2025), reflecting lower policy obligations from assumption changes. No assumption changes embedded in base 2026 guidance, but high end of guidance range ($15.30 EPS) incorporates possibility of additional assumption updates if favorable experience continues.

Normalized life margin improved to 41% in 2025 from 39.7% in 20242023 normalized margin was 38%2026 guidance range $14.60-$15.30; high end reflects potential assumption benefitAssumption changes are cumulative catch-up adjustments from LDTI transition date (Jan 1, 2021)

Sunit Kamath · Jefferies

Can you size the extraordinary dividend and clarify whether remeasurement gains should already be reflected in long-term assumptions if mortality is expected to remain favorable?

Extraordinary dividend was $80 million in 2025. Remeasurement gains not immediately incorporated into assumptions because management wants to see trends emerge quarter-to-quarter before adjusting long-term assumptions. Reluctant to move assumptions based on short-term favorable experience; current long-term assumptions close to pre-pandemic levels while recent experience is more favorable.

Extraordinary dividend: $80 millionCurrent long-term assumptions close to pre-pandemic mortality levelsRecent experience more favorable than long-term assumptionsPotential pull-forward of pandemic deaths being considered in assumption stability

Answers to last quarter's watch list

Q3 remeasurement gain in $110–160M range. Yes — Q3 included a $134.3M pre-tax assumption-update remeasurement gain ($130.9M life + $3.4M health), within the pre-announced range. Total life remeasurement including experience was $149.5M. Status: Resolved positively
Bermuda entity established by year-end with first transaction executed. Management reaffirmed it "anticipates executing the first reinsurance transaction by the end of 2025" with an update on the next call. Reciprocal jurisdiction status (and the associated cash-flow benefit) requires two accounting periods, pushing parent cash flow uplift to 2027 at earliest. Status: Continue monitoring
DTC life premium turns positive YoY. No — DTC life premium was -0.6% YoY, a tick better than Q2's -1% but still negative. Management attributed the lag to prior-year sales declines still flowing through earned premium. Status: Continue monitoring
Agent count growth sustains above mid-single-digits. Mixed — Family Heritage producing agent count +9% YoY (1,553 agents) is strong, but American Income (+2%) and Liberty National (+1%) producing agent counts are running below mid-single-digits. AIL hires +17% YoY is the leading indicator management is leaning on for 2026 reacceleration. Status: Partially resolved
Health underwriting margin holds in 25–27% band. Beat on reported (~28.0%); normalized 27.2% is at the top of the band. Medicare Supplement sales benefiting from Medicare Advantage disruption; rate-increase pricing fully effective. Status: Resolved positively
Share repurchases pace toward $600–650M for FY. Exceeded — Q3 buybacks were $113M (840,242 shares at $134.17 avg). Management raised the FY2025 target to ~$685M, funded in part by an extraordinary subsidiary dividend approved this quarter. Status: Resolved positively (and raised)

What to watch into next quarter

Bermuda captive execution by year-end. Management reaffirmed targeting the first reinsurance transaction by 12/31/2025. A Q4 release without an executed transaction would push the structural capital-return story into 2026; either way, the cash-flow benefit doesn't hit parent excess cash flow until 2027 given the two-accounting-period reciprocal jurisdiction rule.

DTC life premium turns positive YoY. Premium is now -0.6% after Q2's -1% and consecutive quarters of net sales improvement (DTC net sales +13% this quarter). Management guided DTC FY2026 net sales to low-single-digit growth — a positive Q4 premium print would finally validate reinstating marketing spend.

Normalized life UW margin trajectory. Q3 normalized life UW margin of 41.5% (vs. 40.4% PY) anchors the FY2026 life UW margin guide of 40–43%. Watch whether normalized margin holds at or above 41.5% in Q4 — that's the mechanism that supports the upper half of the 2026 EPS range.

Health underwriting margin holds in the 25–27% guide band. Normalized Q3 was 27.2% — at the top of the band. Sustained outperformance would support a band raise; reversion would call into question whether the 2025 rate increases are durable. FY2026 guide is 24–27%, implying some normalization.

Worksite platform and recruiting CRM rollout progress at Liberty National. Management cited 20%+ premium-per-worksite gains and an enterprise rollout into early 2026. Q4 commentary on producing agent counts at LN and AIL beyond the recruiting (+17% AIL hires) will signal whether the productivity story is broadening.

Sources

  1. Globe Life Q3 FY2025 earnings release — https://www.sec.gov/Archives/edgar/data/320335/000032033525000060/q3fy2025earningsrelease.htm
  2. Globe Life Q3 FY2025 earnings call Q&A excerpts (BMO, TD Cowen, J.P. Morgan, Piper Sandler exchanges)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.